Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.

López-Martínez A, O'Brien NM, Caro-Vega Y, Crabtree-Ramírez B, Sierra-Madero J.

J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):155-60. doi: 10.1097/QAI.0b013e31823ff035.

PMID:
22107816
2.
3.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.

AIDS. 2005 Apr 29;19(7):685-94.

PMID:
15821394
5.

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.

Elion R, Cohen C, Gathe J, Shalit P, Hawkins T, Liu HC, Mathias AA, Chuck SL, Kearney BP, Warren DR; GS-US-216-0105 Study Team.

AIDS. 2011 Sep 24;25(15):1881-6. doi: 10.1097/QAD.0b013e32834b4d48.

PMID:
21811136
6.

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.

Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Wirtz V, Lataillade M, Absalon J, McGrath D; CASTLE Study Team.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):323-32. doi: 10.1097/QAI.0b013e3181c990bf.

PMID:
20032785
7.

Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD; HIV Outpatient Study Investigators.

Ann Intern Med. 2003 Apr 15;138(8):620-6.

PMID:
12693883
8.

Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.

van Leth F, Wit FW, Reiss P, Schattenkerk JK, van der Ende ME, Schneider MM, Mulder JW, Frissen PH, de Wolf F, Lange JM.

HIV Med. 2004 Mar;5(2):74-81.

9.

CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.

McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.

Clin Infect Dis. 2005 Dec 1;41(11):1662-70. Epub 2005 Oct 19.

PMID:
16267741
11.
12.

Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.

Bickel M, Bodtländer A, Knecht GK, Stephan C, von Hentig N, Kurowski M, Gute P, Klauke S, Lutz T.

J Antimicrob Chemother. 2009 Dec;64(6):1260-4. doi: 10.1093/jac/dkp348. Epub 2009 Sep 22.

PMID:
19776037
13.

Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.

Bongiovanni M, Chiesa E, Di Biagio A, Meraviglia P, Capetti A, Tordato F, Cicconi P, Biasi P, Bini T, d'Arminio Monforte A.

J Antimicrob Chemother. 2005 Jun;55(6):1003-7. Epub 2005 Apr 11.

PMID:
15824089
14.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
15.
16.
17.

High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.

Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM.

J Antimicrob Chemother. 2009 Feb;63(2):380-8. doi: 10.1093/jac/dkn471. Epub 2008 Nov 25.

PMID:
19036752
18.

Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).

Podzamczer D, Andrade-Villanueva J, Clotet B, Taylor S, Rockstroh JK, Reiss P, Domingo P, Gellermann HJ, de Rossi L, Cairns V, Soriano V.

HIV Med. 2011 Jul;12(6):374-82. doi: 10.1111/j.1468-1293.2011.00917.x. Epub 2011 Apr 24.

19.

Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.

Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.

Clin Infect Dis. 2006 Jan 1;42(1):136-44. Epub 2005 Nov 30.

PMID:
16323104
20.

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A.

Clin Infect Dis. 2009 Nov 15;49(10):1591-601. doi: 10.1086/644769.

PMID:
19842973

Supplemental Content

Support Center